^
9d
Systematic multiomics analysis and in vitro experiments suggest that ITGA5 could serve as a promising therapeutic target for ccRCC. (PubMed, Cancer Cell Int)
Our findings clarified the adverse outcome induced by high expression of ITGA5 in ccRCC patients. In vitro experiments and bioinformatical analysis identified ITGA5 function as predominantly cell proliferation, migration, angiogenesis, and macrophage recruitment. Further, we predicted immune infiltration and medication sensitivity regulation by ITGA5 and proposed a joint use of ITGA5 inhibitors and anti-angiogenetic drugs as a potential potent therapeutic strategy.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • VHL (von Hippel-Lindau tumor suppressor) • ITGA5 (Integrin Subunit Alpha 5)
|
VHL mutation
|
sunitinib • pazopanib • Inlyta (axitinib) • motesanib (AMG 706)
3ms
ELF4 was a prognostic biomarker and related to immune infiltrates in glioma. (PubMed, J Cancer)
Molecular docking analysis revealed ELF4 might be targeted by drugs/compounds, including Veliparib (ABT-888), Motesanib (AMG 706), and EHT 1864. Genomic analysis revealed that, in LGG, in the low ELF4 expression subgroup, IDH1 demonstrated a higher mutation rate, and TP53 and ATRX Chromatin Remodeler (ATRX) displayed the lower mutation rates, than the high ELF4 expression group. Our research suggests that ELF4 may contribute to the prognostic assessment of glioma and personalized medicine.
Journal • PARP Biomarker
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IL6 (Interleukin 6) • ATRX (ATRX Chromatin Remodeler) • IL2 (Interleukin 2) • IFNA1 (Interferon Alpha 1) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
veliparib (ABT-888) • motesanib (AMG 706)
1year
ANRGs impact on gastric cancer progression and drug efficacy: A comprehensive study. (PubMed, Medicine (Baltimore))
The half maximal inhibitory concentration (IC50) values of Ponatinib (ap.24534), Motesanib (amg.706), and Navitoclax (abt.263) were lower in the high-risk group, indicating that patients in the high-risk group were more sensitive to these chemotherapy drugs, meaning with better clinical outcomes. Our study identified key genes based on ANRGs and developed a novel gene signature for predicting the prognosis of GC patients and understanding the relationship between immunity and tumor mutation burden. Additionally, we identified chemotherapeutic drugs that can guide GC treatment and elucidated the binding affinity between specific targeted drugs and distinct protein sites, providing novel insights for the precise treatment of GC patients.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • EGF (Epidermal growth factor) • ZBTB7A (Zinc finger and BTB domain containing 7A) • ANXA5 (Annexin A5) • CCN1 (Cellular Communication Network Factor 1)
|
Iclusig (ponatinib) • navitoclax (ABT 263) • motesanib (AMG 706)
1year
A novel prognostic N-methylguanosine-related long non-coding RNA signature in clear cell renal cell carcinoma. (PubMed, Sci Rep)
High-risk group of patients was more susceptible to A.443654, A.770041, ABT.888, AMG.706, and AZ628. Quantitative real-time polymerase chain reaction (qRT-PCR) exhibited that the expression levels of LINC01507, AC093278.2 were very high in all five ccRCC cell lines, AC084876.1 was upregulated in all ccRCC cell lines except 786-O, and the levels of AL118508.1 and DUXAP8 were upregulated in the Caki-1 cell line. This risk model may be promising for the clinical prediction of prognosis and immunotherapeutic responses in patients with ccRCC.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • DUXAP8 (Double Homeobox A Pseudogene 8)
|
TMB-L
|
veliparib (ABT-888) • AZ 628 • motesanib (AMG 706) • A 443654
1year
A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma. (PubMed, Front Immunol)
The low-risk group was sensitive to the immune checkpoint PD-1 inhibitor, and the high-risk group exhibited lower inhibitory concentration values by 50% for 24 drugs, including AG.014699, AMG.706, and AZD6482. The prognostic stratification framework of patients with OS based on ARGs, such as BNIP3 and CXCL12, may lead to more efficient clinical management.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
Rubraca (rucaparib) • AZD6482 • motesanib (AMG 706)
over1year
Predicting response of immunotherapy and targeted therapy and prognosis characteristics for renal clear cell carcinoma based on m1A methylation regulators. (PubMed, Sci Rep)
"pRRophetic" package screened five potential small molecule drugs (A.443654, A.770041, ABT.888, AG.014699, AMG.706). Finally, polymerase chain reaction (PCR) showed the expression of YTHN6-Methyladenosine RNA Binding Protein 1[YTHDF1], TRNA Methyltransferase 61B [TRMT61B], TRNA Methyltransferase 10C [TRMT10C] and AlkB Homolog 1[ALKBH1] in ccRCC cell lines. To sum up, the prognosis risk model we created not only has good predictive value, but also can provide guidance for accurately predicting the prognosis of ccRCC.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
Rubraca (rucaparib) • veliparib (ABT-888) • motesanib (AMG 706) • A 443654
over1year
A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer. (PubMed, Front Pharmacol)
Drug sensitivity analysis showed that AMG.706, CCT007093, and CHIR.99021 were potential targeted drugs for the TNBCSASP1 subtype...Survival analysis showed that overall survival was significantly shorter in triple-negative breast cancer patients with high FAM3B expression. A senescence-associated signature with different modification patterns has critical potential for providing a better understanding of TNBC biological processes, and FAM3B might serve as an applicable target for TNBC therapy.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
TP53 mutation
|
motesanib (AMG 706)
almost2years
Angiogenesis-related gene signatures reveal the prognosis of cervical cancer based on single cell sequencing and co-expression network analysis. (PubMed, Front Cell Dev Biol)
First we screened the AG gene set from GeneCard website, and then performed angiogenesis-related scores (AGS) per cell from single cell sequencing dataset GSE168652, followed by performing weighted gene co-expression network analysis (WGCNA) for cervical cancer patients according to angiogenesis phenotype...Patients in the low-AGS group were more sensitive to AMG.706, Bosutinib, and Lenalidomide while Imatinib, Pazopanib, and Sorafenib were more recommended to patients in the high-AGS group...Meanwhile, the results showed that TXNDC12 promoted the migration of cervical cancer cells and the tubule-forming ability of endothelial cells. In conclusion, our model based on genes with AG features can effectively assess the prognosis of cervical cancer, and can also provide reference for clinicians to choose immune-related treatments.
Journal • Tumor mutational burden • Gene Signature
|
TMB (Tumor Mutational Burden)
|
TMB-L
|
sorafenib • imatinib • lenalidomide • pazopanib • Bosulif (bosutinib) • motesanib (AMG 706) • GS-168
almost2years
Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer. (PubMed, Ann Transl Med)
The sensitivity of multiple antitumor drugs was negatively related to risk score, including AR-42, AS605240, FK866, TAK-715, and tubastatin A, while the sensitivity of some antitumor drugs, such as AMG-706, BX-795, and RO-3306, were positively correlated with risk score. Our study established and verified a novel clinical risk signature with cuproptosis-related lncRNAs that may predict therapy response and prognosis with robust and stable accuracy in patients with BLCA and enhance the personalized management of this patient population.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
daporinad (APO866) • motesanib (AMG 706)
over2years
MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling. (PubMed, Signal Transduct Target Ther)
In addition, AMG 706, a previously documented inhibitor for endothelial cell proliferation, is identified as a potential agonist for MrgprF, and can impede tumor growth both in vitro and in vivo. Taken together, our findings suggest that MrgprF, a novel tumor suppressor in cutaneous melanoma, may be useful as a therapeutic target in the future.
Journal
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
motesanib (AMG 706)